{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T20:16:37Z","timestamp":1776975397483,"version":"3.51.4"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T00:00:00Z","timestamp":1357689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Inhaled treprostinil is a prostacyclin analog approved for the treatment of pulmonary arterial hypertension (<jats:styled-content style=\"fixed-case\">PAH<\/jats:styled-content>) that may provide a more convenient treatment option for patients receiving inhaled iloprost while maintaining the clinical benefit of inhaled prostacyclin therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>In this open\u2010label safety study, 73 <jats:styled-content style=\"fixed-case\">PAH<\/jats:styled-content> patients were enrolled with primarily <jats:styled-content style=\"fixed-case\">W<\/jats:styled-content>orld <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>ealth <jats:styled-content style=\"fixed-case\">O<\/jats:styled-content>rganization <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>lass <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> (56%) or <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> (42%) symptoms. At baseline, most patients (93%) were receiving 5\u00a0\u03bcg of iloprost per dose but 38% of patients reported a dosing frequency below the labeled rate of 6\u20139 times daily. Patients initiated inhaled treprostinil at 3 breaths four times daily (qid) at the immediate next scheduled iloprost dose. The primary objective was to assess the safety of rapid transition from iloprost to inhaled treprostinil; clinical status and quality of life were also assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Most patients (84%) achieved the target treprostinil dose of 9 breaths qid and remained on study until transition to commercial therapy (89%). The most frequent adverse events (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s) were cough (74%), headache (44%), and nausea (30%), and five patients prematurely discontinued study drug due to <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content> (n\u00a0=\u00a03), disease progression (n\u00a0=\u00a01), or death (n\u00a0=\u00a01). At week 12, the time spent on daily treatment activities was reduced compared to baseline, with a mean total savings of 1.4\u00a0h per day. Improvements were also observed at week 12 for 6\u2010min walk distance (+16.0; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001), <jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>\u2010terminal pro\u2010<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\u2010type natriuretic peptide (\u221274\u00a0pg\/mL; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.001), and the <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>ambridge <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>ulmonary <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>ypertension <jats:styled-content style=\"fixed-case\">O<\/jats:styled-content>utcome <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>eview (all domains <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Pulmonary arterial hypertension patients can be safely transitioned from inhaled iloprost to inhaled treprostinil while maintaining clinical status.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1755-5922.12008","type":"journal-article","created":{"date-parts":[[2012,9,13]],"date-time":"2012-09-13T11:15:14Z","timestamp":1347534914000},"page":"38-44","source":"Crossref","is-referenced-by-count":27,"title":["Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension"],"prefix":"10.1111","volume":"31","author":[{"given":"Robert C.","family":"Bourge","sequence":"first","affiliation":[{"name":"University of Alabama at Birmingham Birmingham AL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor F.","family":"Tapson","sequence":"additional","affiliation":[{"name":"Duke University Medical Center Durham NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeenat","family":"Safdar","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond L.","family":"Benza","sequence":"additional","affiliation":[{"name":"Allegheny General Hospital Pittsburgh PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard N.","family":"Channick","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika B.","family":"Rosenzweig","sequence":"additional","affiliation":[{"name":"Columbia Presbyterian Medical Center New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelley","family":"Shapiro","sequence":"additional","affiliation":[{"name":"David Geffen UCLA School of Medicine, Greater Los Angeles VA Healthcare System Los Angeles CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. James","family":"White","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center Rochester NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher Shane","family":"McSwain","sequence":"additional","affiliation":[{"name":"United Therapeutics Corp. Research Triangle Park NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen Karl","family":"Gotzkowsky","sequence":"additional","affiliation":[{"name":"United Therapeutics Corp. Research Triangle Park NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C.","family":"Nelsen","sequence":"additional","affiliation":[{"name":"United Therapeutics Corp. Research Triangle Park NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis J.","family":"Rubin","sequence":"additional","affiliation":[{"name":"UCSD Medical Center San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.01.004"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.02.036"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340504"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.02.029"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040291"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.66.2.334"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.6.2106079"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.01.027"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.2.9810008"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020204"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.97.10051084"},{"key":"e_1_2_8_13_1","unstructured":"Actelion Pharmaceuticals Ltd.: Ventavis (Iloprost) inhalation soultion.United States Food and Drug Administration Drug Product Label.2011."},{"key":"e_1_2_8_14_1","unstructured":"United Therapeutics Corporation: Tyvaso (Treprostinil) inhalation solution.United States Food and Drug Administration Drug Product Label.2011."},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-005-3513-4"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-2-12"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200408000-00010"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2004.01.003"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.5.1452"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-6-92"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.04.016"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2010.02.020"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00069708"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2010.01468.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01123.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2011.04.011"},{"key":"e_1_2_8_27_1","unstructured":"McConnellJ HobbsK ElwingJ PushkinR.RESPIRE Registry: Inhalation Times and Treatment Adherence of Iloprost Delivered at 10\u00a0\u03bcg\/mL and 20\u00a0\u03bcg\/mL Concentrations in Patients with Pulmonary Arterial Hypertension. PHA: 9th International PH Conference and Scientific Sessions.2010."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.05.070"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007309708"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1755-5922.12008","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1755-5922.12008","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1755-5922.12008","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1755-5922.12008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T03:36:52Z","timestamp":1698637012000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1755-5922.12008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,9]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/1755-5922.12008"],"URL":"https:\/\/doi.org\/10.1111\/1755-5922.12008","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"value":"1755-5914","type":"print"},{"value":"1755-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,9]]}}}